0000000000490033

AUTHOR

Floriano Rosina

showing 15 related works from this author

Overcoming a “Probable” Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature

2010

Serum anti-mitochondrial antibodies (AMA) are the serological hallmark of primary biliary cirrhosis (PBC), yet up to 15% of PBC sera are AMA negative at routine indirect immunofluorescence (IIF) while being referred to as “probable” cases. The diagnostic role of PBC-specific antinuclear antibodies (ANA) remains to be determined. We will report herein data on the accuracy of new laboratory tools for AMA and PBC-specific ANA in a large series of PBC sera that were AMA-negative at IIF. We will also provide a discussion of the history and current status of AMA detection methods. We included IIF AMA-negative PBC sera (n = 100) and sera from patients with other chronic liver diseases (n = 104) th…

AdultMaleAnti-nuclear antibodyNuclear dotsPBCSerologyAnticorpo antimitocondrio cirrosi biliare primitivaPrimary biliary cirrhosisAntigenparasitic diseasesHumansImmunology and AllergyMedicineskin and connective tissue diseasesAgedAutoantibodiesAged 80 and overbiologyLiver Cirrhosis Biliarybusiness.industryAutoantibodyIIfGeneral MedicineMiddle Agedmedicine.diseasedigestive system diseasesMitochondriaImmunologybiology.proteinFemaleAntibodybusinessClinical Reviews in Allergy & Immunology
researchProduct

Etiological factors of chronic hepatitis in Italy: a 2014 national survey.

2017

Background The last Italian prevalence survey on chronic hepatitis (CH) conducted in 2001 showed that the hepatitis C virus (HCV) was the main agent associated with CH. Aim The aim of this study was to evaluate epidemiological changes in CH occurring after 13 years. Patients and methods Enrollment of 1392 CH consecutive patients referred to 16 Italian liver units in 2014 scattered all over the country (four in the North, four in the Center, four in the South, and four in the Islands) was performed. Results The mean age of the patients was 58.3 years, with a sex ratio (male/female) of 1.5. HCV infection (also with other etiologies) continues to be the most prevalent etiology (58.1%). However…

nonalcoholic fatty liver diseaseAdultMalemedicine.medical_specialtyPediatricsTime FactorsTime FactorAdolescentHepatitis C virusmedicine.disease_causemetabolic syndrome03 medical and health sciencesYoung Adult0302 clinical medicinechronic hepatitiRisk FactorsEpidemiologyNonalcoholic fatty liver diseasemedicinePrevalenceHumansAgedHepatitis ChronicHepatitisAged 80 and overHepatologybusiness.industryRisk FactorGastroenterologyEntecavirHepatitis CHealth SurveyHepatitis BHepatitis C ChronicMiddle Agedmedicine.diseaseHealth SurveysItaly030220 oncology & carcinogenesisEtiology030211 gastroenterology & hepatologyFemalehepatitis C virus infectionbusinessHumanmedicine.drugEuropean journal of gastroenterologyhepatology
researchProduct

Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis.

2010

A genome-wide association screen for primary biliary cirrhosis risk alleles was performed in an Italian cohort. The results from the Italian cohort replicated IL12A and IL12RB associations, and a combined meta-analysis using a Canadian dataset identified newly associated loci at SPIB (P = 7.9 × 10−11, odds ratio (OR) = 1.46), IRF5-TNPO3 (P = 2.8 × 10−10, OR = 1.63) and 17q12-21 (P = 1.7 × 10−10, OR = 1.38).

Liver CirrhosisOncologyCanadamedicine.medical_specialtyCirrhosisEuropean Continental Ancestry GroupLOCIPRIMARY BILIARY CIRRHOSIS; GENOME WIDE ASSOCIATION; LOCIGenome-wide association studyLocus (genetics)genetics Genome Genome-Wide Association Study Humans Interferon Regulatory Factors Liver CirrhosiBiologyBiliary Meta-Analysis as Topic Odds RatioWhite PeopleArticleGENOME WIDE ASSOCIATIONAlleles Canada European Continental Ancestry Groupprimary biliary cirrhosiPrimary biliary cirrhosisMeta-Analysis as TopicMED/12 - GASTROENTEROLOGIAIL12AInternal medicineOdds RatioGeneticsmedicineHumansAllelegenomeAlleles Canada European Continental Ancestry Group; genetics Genome Genome-Wide Association Study Humans Interferon Regulatory Factors Liver Cirrhosis; Biliary Meta-Analysis as Topic Odds RatioAllelesprimary biliary cirrhosis genome-wide meta-analysesGeneticsLiver Cirrhosis BiliaryBiliaryOdds ratiomedicine.diseasePrimary biliary cirrhosisInterferon Regulatory FactorsCohortGenome-Wide Association Study
researchProduct

White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths

2014

In 2011 the three major Italian gastroenterological scientific societies (AIGO, the Italian Society of Hospital Gastroenterologists and Endoscopists; SIED, the Italian Society of Endoscopy; SIGE, the Italian Society of Gastroenterology) prepared their official document aimed at analysing medical care for digestive diseases in Italy, on the basis of national and regional data (Health Ministry and Lombardia, Veneto, Emilia-Romagna databases) and to make proposals for planning of care. Digestive diseases were the first or second cause of hospitalizations in Italy in 1999–2009, with more than 1,500,000 admissions/year; however only 5–9% of these admissions was in specialized Gastroenterology un…

MaleGastrointestinal DiseasesTreatment outcomeDiseasesMedical careGastroenterologyCancer; Digestive diseases; Emergency; Gastroenterology; Gastrointestinal bleeding; Hospital discharge record; Hospital stay; Mortality; Adolescent; Adult; Aged; Aged 80 and over; Child; Child Preschool; Emergencies; Female; Gastroenterology; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Health Planning; Health Services; Health Services Needs and Demand; Hospital Mortality; Hospital Units; Humans; Incidence; Infant; Infant Newborn; Italy; Length of Stay; Male; Middle Aged; Prevalence; Societies Medical; Treatment Outcome; Young AdultHealth servicesWhite paperDigestive diseaseitaly80 and overPrevalenceMedicineCancer; Digestive diseases; Emergency; Gastroenterology; Gastrointestinal bleeding; Hospital discharge record; Hospital stay; Mortality; Adolescent; Adult; Aged; Aged 80 and over; Child; Child Preschool; Emergencies; Female; Gastroenterology; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Health Planning; Health Services; Health Services Needs and Demand; Hospital Mortality; Hospital Units; Humans; Incidence; Infant; Infant Newborn; Italy; Length of Stay; Male; Middle Aged; Prevalence; Societies Medical; Treatment Outcome; Young Adult; Hepatology; GastroenterologyHospital MortalityChildSocieties MedicalCancerAged 80 and overSettore MED/12 - GastroenterologiaHospital stayIncidenceIncidence (epidemiology)GastroenterologyHealth ServicesMiddle AgedDigestive diseases Emergency Gastroenterology Gastrointestinal bleeding Hospital discharge record Hospital stay MortalityTreatment OutcomeChild PreschoolFemaleChristian ministryGastrointestinal HemorrhageHospital UnitsHospital discharge recordAdultgastroenterology; Diseases; italymedicine.medical_specialtyAdolescentYoung AdultCase mix indexMedicalInternal medicineHumansCancer Digestive diseases Emergency Gastroenterology Gastrointestinal bleeding Hospital discharge record Hospital stay MortalityMortalityPreschoolGastrointestinal bleedingAgedHealth Services Needs and DemandHepatologybusiness.industryInfant NewbornInfantLength of StayHepatologyNewbornHealth PlanningEmergencyDigestive diseasesEmergenciesSocietiesbusinessDigestive and Liver Disease
researchProduct

Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis

2000

Aim: To establish the efficacy of combination therapy with ursodeoxycholic acid (UDCA) and colchicine in patients with symptomatic primary biliary cirrhosis (PBC), defined by the presence of liver cirrhosis, pruritus or bilirubin exceeding 2 mg/mL. Methods: A total of 90 patients were randomly assigned to ursodeoxycholic acid 500 mg/daily plus placebo (UDCA group, n=44), or ursodeoxycholic acid at the same dosage plus colchicine, 1 mg/daily (UDCA/C group, n=46). The two groups were comparable for age, sex, stage of disease, severity of pruritus, bilirubin, and Mayo score. All patients underwent clinical, ultrasonographic, and biochemical examinations at entry and then every 6 months up to 3…

medicine.medical_specialtyCirrhosisHepatologymedicine.diagnostic_testbusiness.industryBiliary cirrhosisGastroenterologyPlacebo-controlled studymedicine.diseasePlaceboGastroenterologyUrsodeoxycholic acidPrimary biliary cirrhosisCholestasisLiver biopsyInternal medicinemedicinePharmacology (medical)businessmedicine.drugAlimentary Pharmacology & Therapeutics
researchProduct

Long-term interferon-α treatment of children with chronic hepatitis delta: A multicentre study

1996

We assessed the efficacy of prolonged interferon-alpha (IFN) therapy in children with chronic hepatitis caused by hepatitis delta virus (HDV) by treating 26 paediatric cases with IFN-alpha 2b (5 MU m-2, then 3 MU m-2 three times weekly for 12 (medium-term group MTG) or 24 months (long-term group, LTG). Compliance and tolerability were acceptable. At the end of therapy a complete biochemical response [normalization of alanine aminotransferase (ALT)] occurred in 12 children (5/13 in MTG and 7/13 in LTG). A relapse occurred after stopping IFN in 10 cases (five in MTG and five in LTG). Two patients from the LTG had normal liver function tests during 12 months of follow-up. Six of the eight hepa…

Malemedicine.medical_specialtyHepatitis B virusAdolescentmedicine.disease_causeGastroenterologyAntiviral AgentsVirusAntigenChronic hepatitisVirologyInternal medicinemedicineHumansHepatitis B e AntigensChildAntigens ViralHepatitisHepatitis B virusHepatologybusiness.industryInterferon-alphaAlanine Transaminasemedicine.diseaseHepatitis DRecombinant ProteinsClinical trialInfectious DiseasesHBeAgTolerabilityImmunologyChronic DiseaseDNA ViralInterferon Type IPatient ComplianceRNA ViralFemaleHepatitis Delta Virusbusiness
researchProduct

Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology

2017

Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. Abstract BACKGROUND: Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. AIM: To assess epidemiological, laboratory and clinical features of liver cirrhosis in Italy in 2014. PATIENTS: Out of the 2557 consecutive subjects evaluated in 16 hospitals located throughout Italy in 2014, 832 (32.6%) had liver cirrhosis and were enrolled in this study. RESULTS: The mean age of subjects was 60.3years, with a male/female ratio of 1.7; 74.9% of cases had Child…

MaleCirrhosisSettore MED/09 - Medicina InternaAlcohol abuseAlcohol abuse; HBV; HCV; Liver cirrhosis; Liver cirrhosis epidemiology; Internal Medicinemedicine.disease_causeGastroenterology0302 clinical medicineRisk FactorsEpidemiologyHBV030212 general & internal medicineLiver Neoplasmsvirus diseasesMiddle AgedHepatitis BHepatitis CAlcoholismItalyLiver NeoplasmHepatocellular carcinomaHCV030211 gastroenterology & hepatologyAlcohol abuse; HBV; HCV; Liver cirrhosis; Liver cirrhosis epidemiology; Aged; Alcoholism; Carcinoma Hepatocellular; Cross-Sectional Studies; Female; Hepatitis B; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Risk Factors; Internal MedicineFemaleHumanmedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusLiver CirrhosiAlcohol abuseLiver cirrhosis epidemiology03 medical and health sciencesInternal medicinemedicineInternal MedicineHumansDecompensationAgedHepatitis B virusCross-Sectional Studiebusiness.industryRisk FactorCarcinomaHepatocellularmedicine.diseaseCross-Sectional StudiesLiver cirrhosisEtiologybusiness
researchProduct

X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

2021

Background & aims: Genome-wide association studies in primary biliary cholangitis (PBC) have failed to find X chromosome (chrX) variants associated with the disease. Here, we specifically explore the chrX contribution to PBC, a sexually dimorphic complex autoimmune disease. Methods: We performed a chrX-wide association study, including genotype data from 5 genome-wide association studies (from Italy, United Kingdom, Canada, China, and Japan; 5244 case patients and 11,875 control individuals). Results: Single-marker association analyses found approximately 100 loci displaying P < 5 × 10-4, with the most significant being a signal within the OTUD5 gene (rs3027490; P = 4.80 × 10-6; odds…

Canadian-US PBC Consortium0301 basic medicineMaleLinkage disequilibriumGenome-wide association studyDiseasePBCSettore MED/03 - GENETICA MEDICALinkage Disequilibrium0302 clinical medicineUK-PBC ConsortiumGenotypeMitochondrial Precursor Protein Import Complex ProteinsItalian PBC Genetics Study GroupOdds RatioX-Wide Association StudyJapan PBC-GWAS ConsortiumX chromosomeGeneticsLiver Cirrhosis BiliaryGastroenterologyForkhead Transcription FactorsDNA-Binding ProteinsShal Potassium Channels030211 gastroenterology & hepatologyFemaleAdultMonosaccharide Transport ProteinsSuperenhancerLocus (genetics)Single-nucleotide polymorphismBiologyProtein Serine-Threonine KinasesPolymorphism Single NucleotideArticleWhite People03 medical and health sciencesAsian PeopleProto-Oncogene ProteinsEndopeptidasesHumansCell LineageGenetic Predisposition to DiseaseMeta-analysiGenetic associationChromosomes Human XGastroenterology & HepatologyHepatology1103 Clinical SciencesMeta-analysis030104 developmental biologyGenetic Loci1114 Paediatrics and Reproductive MedicineMeta-analysis; Superenhancer; X-Wide Association Study1109 NeurosciencesCarrier ProteinsGenome-Wide Association Study
researchProduct

An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.

2021

[BACKGROUND & AIMS] Primary biliary cholangitis (PBC) is a chronic liver disease in which autoimmune destruction of the small intra-hepatic bile ducts eventually leads to cirrhosis. Many patients have inadequate response to licensed medications, motivating the search for novel therapies. Previous genome-wide association studies (GWAS) and meta-analyses (GWMA) of PBC have identified numerous risk loci for this condition, providing insight into its aetiology. We undertook the largest GWMA of PBC to date, aiming to identify additional risk loci and prioritise candidate genes for in silico drug efficacy screening. [METHODS] We combined new and existing genotype data for 10, 516 cases and 20, 77…

Liver CirrhosisALSPAC; ERN RARE-LIVER; Genomic co-localization; Network-based in silico drug efficacy screening; UK-PBC0301 basic medicineCandidate geneALSPAC; ERN RARE-LIVER; Genomic co-localization; Network-based in silico drug efficacy screening; UK-PBC; Genome-Wide Association Study; Humans; Liver Cirrhosis BiliaryItalian PBC Study GroupLD SCORE REGRESSIONJapan-PBC-GWAS ConsortiumGenome-wide association studyLocus (genetics)DiseaseSUSCEPTIBILITYPBCChronic liver diseaseBioinformaticsGENETIC ASSOCIATION1117 Public Health and Health Services03 medical and health sciences0302 clinical medicineUK-PBC ConsortiumGenotypeHumansMedicineNetwork-based in silico drug efficacy screeningGenetic associationScience & TechnologyGastroenterology & HepatologyHepatologyLiver Cirrhosis Biliarybusiness.industryBiliaryChinese PBC Consortium1103 Clinical SciencesALSPACmedicine.diseasePBC Consortia030104 developmental biologyMeta-analysisERN RARE LIVER030211 gastroenterology & hepatologyGenomic co-localizationUK-PBCUS PBC ConsortiumERN RARE-LIVERCanadian PBC ConsortiumbusinessLife Sciences & BiomedicineGenome-Wide Association StudyHuman
researchProduct

Real-world experience with obeticholic acid in patients with primary biliary cholangitis

2021

Background & aims Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. Methods Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level. The primary endpoint was the biochemical response according to Poise criteria; the secondary endpoint was the biochemical response according to normal range criteria, defined as normal levels of bilirubin, alkaline phosphatase (ALP), and alanine aminotransfer…

upper limit of normalCirrhosisALTAMAAutoimmunityantinuclear antibodiesULNPBCGastroenterologyUDCASettore MED/12ULN upper limit of normalobeticholic acidaRR adjusted risk ratio.CRFs case record formAST aspartate transferaseClinical endpointGGT gamma-glutamyl transferaseQCprimary biliary cholangitisGastroenterologyUrsodeoxycholic acidANATCCCirrhosisCholestasiTIPSTreatment Completer CohortANA antinuclear antibodiemedicine.medical_specialtyRRUDCA ursodeoxycholic acidTIPS transjugular intrahepatic portosystemic shuntOCACirrhosiALP alkaline phosphataseautoimmune hepatitismedicine.diseasedigestive system diseasesDiscontinuationKeywords: AIH autoimmune hepatitiQC quality controlchemistrygamma-glutamyl transferaserandomised controlled trialelectronic data captureantimitochondrial antibodiesaspartate transferaseAutoimmune hepatitischemistry.chemical_compoundAIHCRFsImmunology and Allergyadjusted risk ratioANA antinuclear antibodiesRR risk ratioOverall cohortALT alanine transferaseAMA antimitochondrial antibodieCholestasisCRFs case record formsObeticholic acidOverlap PBC-AIHursodeoxycholic acidOCA obeticholic acidTolerabilityalkaline phosphataseRCTResearch Articlemedicine.drugcase record formsContext (language use)AMA antimitochondrial antibodiesInternal medicineEDC electronic data capturetransjugular intrahepatic portosystemic shuntInternal MedicinemedicineRCT randomised controlled trialaRR adjusted risk ratioOClcsh:RC799-869quality controlalanine transferaseASTaRRHepatologybusiness.industryAutoimmunity; Cholestasis; Cirrhosis; Overlap PBC-AIHAIH autoimmune hepatitisTCC Treatment Completer CohortPBC primary biliary cholangitiGGTrisk ratioOC Overall cohortALPlcsh:Diseases of the digestive system. GastroenterologyPBC primary biliary cholangitisbusinessEDC
researchProduct

Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis

2017

Background The joint effect of the interaction of alcohol intake, hepatitis B virus (HBV) and hepatitis C virus (HCV) on the risk of cirrhosis is still unexplored because a large sample size is required for this investigation. Objective Evaluation of interaction of HBV, HCV and alcohol abuse on the risk of cirrhosis. Design We analysed 12,262 consecutive patients with chronic liver disease of various aetiologies referring to 95 Italian liver units in 2001 or 2014. To evaluate the interaction between alcohol abuse, HBV infection, and HCV infection, patients unexposed to either factors were used as reference category. Adjustment for BMI and age was done by multiple logistic regression analysi…

Genetics and Molecular Biology (all)0301 basic medicineLiver CirrhosisRNA virusesMaleChronic HepatitisCirrhosislcsh:MedicineAlcohol abuseHepacivirusSex FactorChronic liver diseasemedicine.disease_causeBiochemistryGastroenterologyChronic Liver Disease0302 clinical medicineRisk FactorsMedicine and Health Scienceslcsh:SciencePathology and laboratory medicineMultidisciplinaryAlcohol ConsumptionHepatitis C virusLiver DiseasesFatty livervirus diseasesHepatitis CHepatitis BMedical microbiologyMiddle AgedHepatitis BHepatitis CCirrhosisOncologyVirusesCoinfection030211 gastroenterology & hepatologyFemalePathogensResearch ArticleHumanAdultmedicine.medical_specialtyHepatitis B virusAlcohol DrinkingLiver CirrhosiGastroenterology and HepatologyMicrobiologyCarcinomas03 medical and health sciencesSex FactorsInternal medicineGastrointestinal TumorsmedicineHumansNutritionAgedHepatitis B virusBiochemistry Genetics and Molecular Biology (all)Flavivirusesbusiness.industryRisk Factorlcsh:ROrganismsViral pathogensBiology and Life SciencesCancers and NeoplasmsHepatocellular Carcinomamedicine.diseaseVirologydigestive system diseasesHepatitis virusesAdult; Aged; Alcohol Drinking; Female; Hepatitis B; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Risk Factors; Sex Factors; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)DietMicrobial pathogensFatty Liver030104 developmental biologyAgricultural and Biological Sciences (all)lcsh:Qbusiness
researchProduct

Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

2014

a b s t r a c t Background: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostly derived from treatment of selected patients enrolled in clinical trials. This study aimed to assess the effectiveness of Peg-interferon/ribavirin therapy in “real world” chronic hepatitis C patients in Italy. Methods: Independent observational multicentre study including consecutive patients receiving Peginterferon/ribavirin in the 18 months before (retrospective phase) and after (prospective phase) the start of the study. Results: 4176 patients were eligible. The final study population consisted of 2051 patients in the retrospective and 2073 in the prospective phase. Sust…

RegistrieMaleCirrhosismedicine.disease_causePolyethylene GlycolGastroenterologyPolyethylene Glycolschemistry.chemical_compoundHepatitis VirusesHepatitis ViruseProspective StudiesViralRegistriesChronicProspective cohort studyDrug CarrierDrug CarriersSettore MED/12 - GastroenterologiaMedicine (all)GastroenterologyRecombinant ProteinMiddle AgedHepatitis CRecombinant ProteinsTreatment OutcomeItalyCombinationRNA ViralPopulation studyDrug Therapy CombinationFemaleHumanmedicine.medical_specialtyGenotypeHepatitis C virusAlpha interferonRibavirin; Sustained virological response (SVR); TreatmentAntiviral AgentsFollow-Up StudieRibavirin; Sustained virological response (SVR); Treatment; Hepatology; GastroenterologyDrug TherapyInternal medicineRibavirinmedicineHumansAntiviral AgentHepatologybusiness.industryRibavirinInterferon-alphaHCV therapyHepatitis C ChronicHepatologymedicine.diseaseClinical trialTreatmentProspective StudiechemistryImmunologyRNARibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; RegistriesbusinessRibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; Registries; Gastroenterology; Hepatology; Medicine (all)Follow-Up StudiesSustained virological response (SVR)
researchProduct

Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy

2017

Background: Gender differences in chronic liver disease (CLD) have been partially investigated. To extend the present knowledge, we evaluated 12,263 patients with CLD enrolled in two national surveys (9997 in 2001 and 2557 in 2014). Methods: The two surveys prospectively recruited patients aged ≥ 18 referring to Italian liver units throughout the country using a similar clinical approach and analytical methods. Results: The overall male to female ratio (M/F) was 1.4 (7138/5124). Compared with females, males were significantly more likely to be younger (52.9 vs. 58.7 yrs.), with HBV infection alone (13.2% vs. 9.2%) and with alcoholic liver disease alone (11.4% vs. 6.9%), but less likely t…

Alcoholic liver diseasePathologyCirrhosisliver diseasesHepatocellular carcinomaPrevalenceChronic liver diseaseGastroenterology0302 clinical medicinecohort studiesEpidemiologymiddle aged030212 general & internal medicinehumansChronic liver diseasesHBV infectionChronic hepatitisadultChronic liver diseaseGeneral MedicineHepatitis CHepatitis BHCV infectionagedInfectious DiseasesItalyyoung adult030211 gastroenterology & hepatologyCohort studyMicrobiology (medical)medicine.medical_specialtyprevalence03 medical and health sciencesInternal medicinemedicineLiver Diseases AlcoholicAlcoholic liver diseases; Chronic hepatitis; Chronic liver diseases; HBV infection; HCV infection; Hepatocellular carcinoma; Microbiology (medical); Infectious DiseasesAlcoholic liver diseases; Chronic hepatitis; Chronic liver diseases; HBV infection; HCV infection; Hepatocellular carcinomabusiness.industryAlcoholic liver diseaseAlcoholic liver diseasesmedicine.diseaseprospective studiessex factorsChronic hepatitihepatitis Bhepatitis Cbusinesschronic diseasealcoholic liver diseases; chronic hepatitis; chronic liver diseases; HBV infection; HCV infection; hepatocellular carcinoma; adult; aged; chronic disease; cohort studies; hepatitis B; hepatitis C; humans; Italy; liver diseases; liver diseases alcoholic; middle aged; prevalence; prospective studies; sex factors; young adultalcoholic
researchProduct

Hepatitis delta infection in Italian patients: towards the end of the story?

2016

Background: The endemicity of hepatitis delta virus infection in Italy has decreased in the last decades. Aim: To evaluate the current epidemiology of chronic delta infection in Italy and to compare the present findings with the corresponding figures from the previous studies. Methods: A cross-sectional study involving 16 referral centres scattered all over the country in 2014. Results: Out of the 513 hepatitis B surface antigen-positive subjects enrolled, 61 (11.9%) were anti-delta positive, with a sex ratio (M/F) of 2.05. The majority (80.3%) of them was 50 years or older, while the proportion of subjects younger than 30 years of age was as low as 3.3%. No difference was detected by geogr…

AdultLiver CirrhosisMaleMicrobiology (medical)HBsAgPediatricsmedicine.medical_specialtyCirrhosisHepatitis D ChronicEpidemiology03 medical and health sciencesLiver disease0302 clinical medicineHBsAgEpidemiologymedicineHumansCirrhosis; Epidemiology; HBsAg; HDV infection; Microbiology (medical); Infectious Diseases030212 general & internal medicineCirrhosis; Epidemiology; HBsAg; HDV infectionChronicCirrhosis; Epidemiology; HBsAg; HDV infection; Adult; Aged; Cross-Sectional Studies; Female; Hepatitis D Chronic; Hepatitis Delta Virus; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Microbiology (medical); Infectious DiseasesAgedCirrhosibusiness.industryGeneral MedicineHepatitis BMiddle Agedmedicine.diseaseHepatitis DHepatitis DCross-Sectional StudiesInfectious DiseasesCirrhosisItalyImmunology030211 gastroenterology & hepatologyFemaleHepatitis Delta VirusViral hepatitisbusinessSex ratioHDV infection
researchProduct

Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study

2017

Background and Aim The universal hepatitis B vaccination for infants and 12-year-old adolescents (the latter limited to the first 12 years of application) was launched in Italy in 1991. Twenty-three years later we evaluated the impact of the vaccination campaign on the burden of HBsAg-positive chronic liver diseases (CLD). Material and Methods 513 HBsAg-positive chronic carriers referring to 16 Italian liver units were investigated and compared with HBsAg carriers enrolled in previous surveys. Results The proportion of inactive carriers decreased from 20.0% in 2001 to 3.3% in 2014, while that of cirrhotic patients increased from 22.6 to 33.2%. Regarding the age class 0–33 (fully covered by …

MaleTime FactorsCirrhosisSettore MED/09 - Medicina InternaHbv vaccination0302 clinical medicinechronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccinationMedicine030212 general & internal medicineChildAged 80 and overVaccinationMiddle AgedVaccinationInfectious DiseasesItalyLiverCarrier StateFemale030211 gastroenterology & hepatologyHbsag carrierAdultHepatitis B virusAdolescentYoung Adult03 medical and health sciencesHepatitis B ChronicChronic hepatitisVirologyHumansHBsAg-positive chronic hepatitis clinical presentationHepatitis B Vaccineschronic hepatitis BHepatitis B AntibodiesHBsAg-positive chronic hepatitisAgedHBsAg chronic carrierHBV vaccinationImmunization Programsbusiness.industrychronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccination; virology; infectious diseasesInfantchronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccination; Virology; Infectious Diseasesmedicine.diseaseVirologyCross-Sectional StudiesHBsAg chronic carriersMulticenter studyHepatitis b vaccinationHBsAg-positive chronic hepatitibusiness
researchProduct